# XORTX Therapeutics Inc.: overview XRTX · Nasdaq · CIK 1729214 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/xrtx.md) · [Financials](/companies/xrtx/financials.md) · [Filings](/companies/xrtx/filings.md) · [Insiders](/companies/xrtx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2019-12-31) | FY (2020-12-31) | FY2021 (2021-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | not reported | not reported | | Free cash flow | $ | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLoss. - Diluted EPS. XBRL not reported. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/xrtx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $52.5k | 23,116 | | New +23,116 | | [StoneX Group Inc.](/funds/913760.md) | 2026-06-30 | $37.9k | 16,369 | | New +16,369 | | [ROYAL BANK OF CANADA](/funds/1000275.md) | 2026-06-30 | $2.0k | 732 | | New +732 | | [NATIONAL BANK OF CANADA /FI/](/funds/926171.md) | 2026-06-30 | $329 | 162 | | New +162 | | [Clearstead Advisors, LLC](/funds/842775.md) | 2026-06-30 | $120 | 55 | | Reduced −222 | | [TD Waterhouse Canada Inc.](/funds/1999606.md) | 2026-06-30 | $19 | 9 | | New +9 | ## Recent filings [All 291 filings](/companies/xrtx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-08 | 20:07 ET | [6-K](/filings/0001171843-26-006540.md) | Report of a foreign private issuer, period 2026-10-08 | 0001171843-26-006540 | | 2026-09-18 | 12:05 ET | [6-K](/filings/0001171843-26-006109.md) | Report of a foreign private issuer, period 2026-09-18 | 0001171843-26-006109 | | 2026-09-10 | 20:17 ET | [6-K](/filings/0001171843-26-005981.md) | Report of a foreign private issuer, period 2026-09-10 | 0001171843-26-005981 | | 2026-09-09 | 20:01 ET | [6-K](/filings/0001185185-26-003895.md) | Report of a foreign private issuer, period 2026-09-09 | 0001185185-26-003895 | | 2026-09-04 | 12:51 ET | [6-K](/filings/0001185185-26-003845.md) | Report of a foreign private issuer, period 2026-09-04 | 0001185185-26-003845 | | 2026-08-28 | 11:00 ET | [6-K](/filings/0001171843-26-005782.md) | Report of a foreign private issuer, period 2026-08-28 | 0001171843-26-005782 | | 2026-08-17 | 10:00 ET | [6-K](/filings/0001171843-26-005562.md) | Report of a foreign private issuer, period 2026-06-30 | 0001171843-26-005562 | | 2026-08-04 | 00:35 ET | [6-K](/filings/0001171843-26-005158.md) | Report of a foreign private issuer, period 2026-07-31 | 0001171843-26-005158 | | 2026-07-29 | 11:00 ET | [6-K](/filings/0001171843-26-004972.md) | Report of a foreign private issuer, period 2026-07-29 | 0001171843-26-004972 | | 2026-06-15 | 11:00 ET | [6-K](/filings/0001171843-26-004112.md) | Report of a foreign private issuer, period 2026-06-15 | 0001171843-26-004112 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-032775.md), filed Mar 20, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1729214 - Tickers: XRTX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: A1 - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.